Results 31 to 40 of about 21,933 (136)

Renal phosphate loss in Iraqi chronic myeloid leukemia patients treated by imatinib mesylate

Iraqi Journal of Hematology, 2020
BACKGROUND: The use of BCR-ABL tyrosine kinase inhibitor imatinib mesylate improved outcomes for patients with chronic myeloid leukemia (CML). Hypophosphatemia is found to be associated with imatinib mesylate use; the exact mechanism of this is not clear
Huda A Al-Taee, Azhar K Athab, Ala Ali
doaj   +1 more source

Targeting SOS1 overcomes imatinib resistance with BCR-ABL independence through uptake transporter SLC22A4 in CML

Molecular Therapy: Oncolytics, 2021
Resistance to the BCR-ABL inhibitor imatinib mesylate poses a major problem for the treatment of chronic myeloid leukemia. Imatinib resistance often results from a secondary mutation in BCR-ABL that interferes with drug binding.
Yanjun Liu, Chuting Li, Rui Su, Zhao Yin, Guiping Huang, Juhua Yang, Zhendong Li, Keda Zhang, Jia Fei   +8 more
doaj   +1 more source

Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity

Turkish Journal of Hematology, 2015
Imatinib mesylate is a small-molecule tyrosine kinase inhibitor (TKi) designed to target c-ABL and BCR-ABL, approved for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors.
Caterina Musolino, Alessandro Allegra, Carmen Mannucci, Sabina Russo, Andrea Alonci, Valerio Maisano, Gioacchino Calapai, Sebastiano Gangemi   +7 more
doaj   +1 more source

Malignant stromal tumor of the stomach with giant cystic liver metastases prior to treatment with imatinib mesylate [PDF]

Vojnosanitetski Pregled, 2013
Introduction. Gastrointestinal stromal tumors (GISTs) are rare and account for 0.1%-3% of all gastrointestinal neoplasms. GISTs are most commonly located in the stomach (60%) and 20%-25% are malignant, with metastases involving the peritoneum or
Čolović Radoje, Micev Marjan, Matić Slavko, Čolović Nataša, Grubor Nikica, Atkinson Dushan Henry   +5 more
doaj   +1 more source

Evaluation of imatinib mesylate (Gleevec) on KAI1/CD82 gene expression in breast cancer MCF-7 cells using quantitative real-time PCR

Asian Pacific Journal of Tropical Biomedicine, 2016
Objective: To evaluate the effect of imatinib mesylate on cell viability, anti cancer effect through modulation of KAI1/CD82 gene expression in breast cancer MCF-7 cell line.
Seyed Ataollah Sadat Shandiz, Marjan Khosravani, Sepideh Mohammadi, Hassan Noorbazargan, Amir Mirzaie, Davoud Nouri Inanlou, Mojgan Dalirsaber Jalali, Hamidreza Jouzaghkar, Fahimeh Baghbani-Arani, Behta Keshavarz-Pakseresht   +9 more
doaj   +1 more source

Prognosic Factors Related to The Complete Hematologic Response (CHR) in 3 Months in Leukemia Granulositic Patients Administered with Imatinib Mesylate

Jurnal Penyakit Dalam Indonesia, 2020
Introduction. The complete hematologic response is an integral part to achieve the complete cytogenetic response target and the major molecular response of imatinib mesylate therapy, although it does not determine the prognosis.
Ikhwan Rinaldi, Ary Harryanto Reksodiputro   +1 more
doaj   +1 more source

The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines [PDF]

, 2009
Background Imatinib mesylate, a selective inhibitor of Abl tyrosine kinase, is efficacious in treating chronic myeloid leukaemia (CML) and Ph+ acute lymphoblastic leukaemia (ALL).
Schwarz, Kerstin, Ruthardt, Martin, Romanski Annette, Romanski, Annette, Ruthardt Martin, Ottmann, Oliver G., Ottmann, Oliver G, Bacic, Biserka, Gwanmesia Patricia, Gwanmesia, Patricia Mambou, Schwarz Kerstin, Ottmann Oliver G, Bacic Biserka   +12 more
core   +1 more source

Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34⁺ cells to imatinib [PDF]

, 2009
<p><b>Objective:</b> To investigate the interaction of imatinib mesylate (IM) with the clinically relevant adenosine triphosphate-binding cassette efflux transporter MDR1 (ABCB1) in cells from patients with chronic myeloid leukemia (CML)
Holyoake, T.L., Jordanides, N.E., Jorgensen, H.G., Hatziieremia, S., Mountford, J.C.   +4 more
core   +1 more source

Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma

OncoImmunology, 2018
Several studies support the notion that the kinase inhibitor Imatinib mesylate exerts off-target effects on cells of the immune system. After our first report of continuous daily oral administration in subjects with relapsed/refractory neuroblastoma (NB,
Fabio Morandi, Loredana Amoroso, Alessandra Dondero, Roberta Castriconi, Stefano Parodi, Roberto Luksch, Fiorina Casale, Aurora Castellano, Alberto Garaventa, Alessandro Moretta, Cristina Bottino, Mirco Ponzoni, Maria Valeria Corrias   +12 more
doaj   +1 more source

Long-term management of canine disseminated granulomatous meningoencephalitis with imatinib mesylate: a case report

Veterinární Medicína, 2019
A seven-year-old Toy Poodle was presented for progressive ataxia and seizure episodes. Magnetic resonance imaging revealed inflammatory lesions in the cerebrum and brainstem.
Joong Hyun Song, Tae Sung Hwang, Hee Chun Lee, Do Hyeon Yu, Byung Joon Seung, Jung Hyang Sur, Dong In Jung   +6 more
doaj   +1 more source